Interested in Catalyst Pharmaceuticals, Inc.? Here are five stocks we like better.
Catalyst Pharmaceuticals stockholders approved the company's merger with Angelini Pharma at a special meeting held on July 8. Under the deal, Angelini Cello Inc. will merge into Catalyst, and Catalyst will become a wholly owned subsidiary of Angelini Pharma.
The merger proposal passed with the required vote of a majority of Catalyst's outstanding shares entitled to vote. Company officials said the final voting results will be announced publicly after certification.
A separate non-binding compensation advisory proposal did not receive stockholder approval, but it was not a condition for completing the merger. Because the merger proposal passed, no adjournment vote was needed and the meeting was concluded.
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals stockholders approved the company's merger with Angelini Pharma at a special meeting held on July 8. Under the deal, Angelini Cello Inc. will merge into Catalyst, and Catalyst will become a wholly owned subsidiary of Angelini Pharma.
The merger proposal passed with the required vote of a majority of Catalyst's outstanding shares entitled to vote. Company officials said the final voting results will be announced publicly after certification.
A separate non-binding compensation advisory proposal did not receive stockholder approval, but it was not a condition for completing the merger. Because the merger proposal passed, no adjournment vote was needed and the meeting was concluded.
2 Biotechs Making Waves With A Single Product in their Pipeline
4 months ago
